DE69032284T2
(de)
|
1989-03-21 |
1998-10-08 |
Vical Inc |
Expression von exogenen polynukleotidsequenzen in wirbeltieren
|
US6867195B1
(en)
|
1989-03-21 |
2005-03-15 |
Vical Incorporated |
Lipid-mediated polynucleotide administration to reduce likelihood of subject's becoming infected
|
FR2676072B1
(fr)
|
1991-05-03 |
1994-11-18 |
Transgene Sa |
Vecteur de delivrance d'arn.
|
US5795587A
(en)
|
1995-01-23 |
1998-08-18 |
University Of Pittsburgh |
Stable lipid-comprising drug delivery complexes and methods for their production
|
US6214966B1
(en)
|
1996-09-26 |
2001-04-10 |
Shearwater Corporation |
Soluble, degradable poly(ethylene glycol) derivatives for controllable release of bound molecules into solution
|
EP0855184A1
(en)
|
1997-01-23 |
1998-07-29 |
Grayson B. Dr. Lipford |
Pharmaceutical composition comprising a polynucleotide and an antigen especially for vaccination
|
US6251665B1
(en)
|
1997-02-07 |
2001-06-26 |
Cem Cezayirli |
Directed maturation of stem cells and production of programmable antigen presenting dentritic cells therefrom
|
US6261281B1
(en)
|
1997-04-03 |
2001-07-17 |
Electrofect As |
Method for genetic immunization and introduction of molecules into skeletal muscle and immune cells
|
AU750106B2
(en)
|
1997-10-07 |
2002-07-11 |
University Of Maryland Biotechnology Institute |
Method for introducing and expressing RNA in animal cells
|
US6432925B1
(en)
|
1998-04-16 |
2002-08-13 |
John Wayne Cancer Institute |
RNA cancer vaccine and methods for its use
|
EP1574210B1
(en)
|
1999-02-26 |
2016-04-06 |
Novartis Vaccines and Diagnostics, Inc. |
Microemulsions with adsorbed macromolecules
|
US6514948B1
(en)
|
1999-07-02 |
2003-02-04 |
The Regents Of The University Of California |
Method for enhancing an immune response
|
ATE289630T1
(de)
|
1999-09-09 |
2005-03-15 |
Curevac Gmbh |
Transfer von mrnas unter verwendung von polykationischen verbindungen
|
WO2001021810A1
(en)
|
1999-09-17 |
2001-03-29 |
Aventis Pasteur Limited |
Chlamydia antigens and corresponding dna fragments and uses thereof
|
US7060291B1
(en)
|
1999-11-24 |
2006-06-13 |
Transave, Inc. |
Modular targeted liposomal delivery system
|
BR0112637A
(pt)
|
2000-07-21 |
2003-06-10 |
Glaxo Group Ltd |
Sequências do vìrus do papiloma códon-otimizadas
|
US6998115B2
(en)
|
2000-10-10 |
2006-02-14 |
Massachusetts Institute Of Technology |
Biodegradable poly(β-amino esters) and uses thereof
|
US7708915B2
(en)
|
2004-05-06 |
2010-05-04 |
Castor Trevor P |
Polymer microspheres/nanospheres and encapsulating therapeutic proteins therein
|
WO2002085434A1
(de)
|
2001-04-21 |
2002-10-31 |
Curevac Gmbh |
Injektionsgerät für rna applikation
|
EP1800697B1
(de)
|
2001-06-05 |
2010-04-14 |
CureVac GmbH |
Stabilisierte mRNA mit erhöhtem G/C-Gehalt für die Gentherapie
|
WO2003011443A2
(en)
|
2001-07-27 |
2003-02-13 |
President And Fellows Of Harvard College |
Laminar mixing apparatus and methods
|
CA2462593A1
(en)
|
2001-10-03 |
2003-04-10 |
Kam W. Leong |
Compositions for oral gene therapy and methods of using same
|
DE10162480A1
(de)
|
2001-12-19 |
2003-08-07 |
Ingmar Hoerr |
Die Applikation von mRNA für den Einsatz als Therapeutikum gegen Tumorerkrankungen
|
NZ535952A
(en)
|
2002-04-04 |
2009-01-31 |
Coley Pharm Gmbh |
Immunostimulatory G,U-containing oligoribonucleotides
|
WO2003092665A2
(en)
|
2002-05-02 |
2003-11-13 |
Massachusetts Eye And Ear Infirmary |
Ocular drug delivery systems and use thereof
|
DE10229872A1
(de)
|
2002-07-03 |
2004-01-29 |
Curevac Gmbh |
Immunstimulation durch chemisch modifizierte RNA
|
ES2429338T3
(es)
|
2002-12-23 |
2013-11-14 |
Vical Incorporated |
Vacuna basada en polinucleótidos optimizados por codones contra infección por citomegalovirus humano
|
PT1651666E
(pt)
|
2003-07-11 |
2009-08-28 |
Alphavax Inc |
Vacinas de citomegalovírus à base de alfavírus
|
DE10347710B4
(de)
|
2003-10-14 |
2006-03-30 |
Johannes-Gutenberg-Universität Mainz |
Rekombinante Impfstoffe und deren Verwendung
|
WO2005072710A2
(en)
|
2004-01-28 |
2005-08-11 |
Johns Hopkins University |
Drugs and gene carrier particles that rapidly move through mucous barriers
|
US20050232981A1
(en)
|
2004-04-15 |
2005-10-20 |
Ben-Sasson Shmuel A |
Compositions capable of facilitating penetration across a biological barrier
|
EP1856179B1
(en)
|
2004-12-10 |
2013-05-15 |
Kala Pharmaceuticals, Inc. |
Functionalized poly (ether-anhydride) block copolymers
|
GB0504436D0
(en)
*
|
2005-03-03 |
2005-04-06 |
Glaxosmithkline Biolog Sa |
Vaccine
|
US7638558B2
(en)
|
2005-04-01 |
2009-12-29 |
Intezyne Technologies, Inc. |
Polymeric micelles for drug delivery
|
EP1885403B1
(en)
|
2005-04-12 |
2013-05-08 |
Nektar Therapeutics |
Poly(ethyleneglycol) conjugates of Lysostaphin
|
PL2279758T3
(pl)
|
2005-06-16 |
2015-07-31 |
Nektar Therapeutics |
Koniugaty mające degradowalne połączenie oraz odczynniki polimerowe użyteczne w wytwarzaniu takich koniugatów
|
LT2578685T
(lt)
|
2005-08-23 |
2019-06-10 |
The Trustees Of The University Of Pennsylvania |
Rnr, apimančios modifikuotus nukleozidus ir jų panaudojimo būdai
|
DE102006007433A1
(de)
|
2006-02-17 |
2007-08-23 |
Curevac Gmbh |
Adjuvanz in Form einer Lipid-modifizierten Nukleinsäure
|
EP1986695B1
(en)
|
2006-02-21 |
2015-06-03 |
Nektar Therapeutics |
Segmented degradable polymers and conjugates made therefrom
|
JP5630998B2
(ja)
|
2006-05-15 |
2014-11-26 |
マサチューセッツ インスティテュート オブ テクノロジー |
機能的粒子のためのポリマー
|
AU2007280690C1
(en)
|
2006-07-31 |
2012-08-23 |
Curevac Gmbh |
Nucleic acid of formula (I): GIXmGn, or (II): CIXmCn, in particular as an immune-stimulating agent/adjuvant
|
ATE498393T1
(de)
|
2006-09-08 |
2011-03-15 |
Univ Johns Hopkins |
Zusammensetzungen zur transportintensivierung durch die schleimhaut
|
DE102006051516A1
(de)
|
2006-10-31 |
2008-05-08 |
Curevac Gmbh |
(Basen-)modifizierte RNA zur Expressionssteigerung eines Proteins
|
ES2447516T3
(es)
|
2006-12-21 |
2014-03-12 |
Stryker Corporation |
Formulaciones de liberación sostenida que comprenden cristales BMP-7
|
DE102007001370A1
(de)
|
2007-01-09 |
2008-07-10 |
Curevac Gmbh |
RNA-kodierte Antikörper
|
US20100330122A1
(en)
*
|
2007-07-19 |
2010-12-30 |
Gale Smith |
VARICELLA ZOSTER VIRUS VIRUS-LIKE PARTICLES (VLPs) AND ANTIGENS
|
WO2009030254A1
(en)
|
2007-09-04 |
2009-03-12 |
Curevac Gmbh |
Complexes of rna and cationic peptides for transfection and for immunostimulation
|
ES2376175T3
(es)
|
2007-09-28 |
2012-03-09 |
Bind Biosciences, Inc. |
Direccionamiento a células de c�?ncer usando nanopart�?culas.
|
US10736848B2
(en)
|
2007-10-12 |
2020-08-11 |
Massachusetts Institute Of Technology |
Vaccine nanotechnology
|
PL2279254T3
(pl)
|
2008-04-15 |
2017-11-30 |
Protiva Biotherapeutics Inc. |
Nowe preparaty lipidowe do dostarczania kwasów nukleinowych
|
US8613951B2
(en)
|
2008-06-16 |
2013-12-24 |
Bind Therapeutics, Inc. |
Therapeutic polymeric nanoparticles with mTor inhibitors and methods of making and using same
|
SI2774608T1
(sl)
|
2008-06-16 |
2020-02-28 |
Pfizer Inc. |
Polimerni nanodelci, napolnjeni z zdravilom, ter postopki za njihovo pripravo in uporabo
|
HUE035770T2
(en)
|
2008-06-16 |
2018-05-28 |
Pfizer |
Process for the preparation of diblock copolymers functionalized with targeting material for use in the preparation of therapeutic nanoparticles
|
EP2309991B1
(en)
|
2008-06-16 |
2019-03-06 |
Pfizer Inc |
Therapeutic polymeric nanoparticles comprising vinca alkaloids and methods of making and using same
|
WO2010030763A2
(en)
|
2008-09-10 |
2010-03-18 |
Bind Biosciences, Inc. |
High throughput fabrication of nanoparticles
|
WO2010037408A1
(en)
|
2008-09-30 |
2010-04-08 |
Curevac Gmbh |
Composition comprising a complexed (m)rna and a naked mrna for providing or enhancing an immunostimulatory response in a mammal and uses thereof
|
EP2350043B9
(en)
|
2008-10-09 |
2014-08-20 |
TEKMIRA Pharmaceuticals Corporation |
Improved amino lipids and methods for the delivery of nucleic acids
|
KR102264822B1
(ko)
|
2008-11-10 |
2021-06-14 |
알닐람 파마슈티칼스 인코포레이티드 |
치료제 운반용 신규 지질 및 조성물
|
WO2010057203A2
(en)
|
2008-11-17 |
2010-05-20 |
The Board Of Regents Of The University Of Texas System |
Hdl particles for delivery of nucleic acids
|
EP2379064B1
(en)
|
2008-12-15 |
2020-02-26 |
Pfizer Inc. |
Long circulating nanoparticles for sustained release of therapeutic agents
|
WO2010088927A1
(en)
|
2009-02-09 |
2010-08-12 |
Curevac Gmbh |
Use of pei for the improvement of endosomal release and expression of transfected nucleic acids, complexed with cationic or polycationic compounds
|
JP5622254B2
(ja)
|
2009-03-31 |
2014-11-12 |
国立大学法人東京大学 |
二本鎖リボ核酸ポリイオンコンプレックス
|
US9764012B2
(en)
|
2009-04-01 |
2017-09-19 |
University Of Miami |
Vaccine compositions and methods of use thereof
|
WO2010127159A2
(en)
|
2009-04-30 |
2010-11-04 |
Intezyne Technologies, Incorporated |
Polymeric micelles for polynucleotide encapsulation
|
WO2011000106A1
(en)
|
2009-07-01 |
2011-01-06 |
Protiva Biotherapeutics, Inc. |
Improved cationic lipids and methods for the delivery of therapeutic agents
|
WO2011005799A2
(en)
|
2009-07-06 |
2011-01-13 |
Novartis Ag |
Self replicating rna molecules and uses thereof
|
CA2816925C
(en)
|
2009-11-04 |
2023-01-10 |
The University Of British Columbia |
Nucleic acid-containing lipid particles and related methods
|
WO2011069529A1
(en)
|
2009-12-09 |
2011-06-16 |
Curevac Gmbh |
Mannose-containing solution for lyophilization, transfection and/or injection of nucleic acids
|
EA201290497A1
(ru)
|
2009-12-15 |
2013-01-30 |
Байнд Байосайенсиз, Инк. |
Терапевтические полимерные наночастицы, включающие кортикостероиды, и способы получения таковых
|
US9295649B2
(en)
|
2009-12-15 |
2016-03-29 |
Bind Therapeutics, Inc. |
Therapeutic polymeric nanoparticle compositions with high glass transition temperature or high molecular weight copolymers
|
WO2011084521A2
(en)
|
2009-12-15 |
2011-07-14 |
Bind Biosciences, Inc. |
Therapeutic polymeric nanoparticles comprising epothilone and methods of making and using same
|
WO2012082165A1
(en)
|
2010-01-24 |
2012-06-21 |
Novartis Ag |
Irradiated biodegradable polymer microparticles
|
WO2011119262A1
(en)
|
2010-03-26 |
2011-09-29 |
Cerulean Pharma Inc. |
Methods and systems for generating nanoparticles
|
US20110262491A1
(en)
|
2010-04-12 |
2011-10-27 |
Selecta Biosciences, Inc. |
Emulsions and methods of making nanocarriers
|
EP2387999A1
(en)
|
2010-05-21 |
2011-11-23 |
CureVac GmbH |
Histidine-containing solution for transfection and/or injection of nucleic acids and uses thereof
|
US8802863B2
(en)
|
2010-05-24 |
2014-08-12 |
Sirna Therapeutics, Inc. |
Amino alcohol cationic lipids for oligonucleotide delivery
|
WO2011163483A2
(en)
|
2010-06-25 |
2011-12-29 |
Massachusetts Institute Of Technology |
Polymers for biomaterials and therapeutics
|
EP2590626B1
(en)
|
2010-07-06 |
2015-10-28 |
GlaxoSmithKline Biologicals SA |
Liposomes with lipids having an advantageous pka-value for rna delivery
|
US9192661B2
(en)
|
2010-07-06 |
2015-11-24 |
Novartis Ag |
Delivery of self-replicating RNA using biodegradable polymer particles
|
PT2590676T
(pt)
|
2010-07-06 |
2016-11-04 |
Glaxosmithkline Biologicals Sa |
Partículas de transferência de tipo virião para moléculas de arn auto-replicante
|
WO2012006369A2
(en)
*
|
2010-07-06 |
2012-01-12 |
Novartis Ag |
Immunisation of large mammals with low doses of rna
|
EP3449910A1
(en)
|
2010-07-06 |
2019-03-06 |
GlaxoSmithKline Biologicals S.A. |
Cationic oil-in-water emulsions
|
CA2801523C
(en)
|
2010-07-30 |
2021-08-03 |
Curevac Gmbh |
Complexation of nucleic acids with disulfide-crosslinked cationic components for transfection and immunostimulation
|
EP3578205A1
(en)
|
2010-08-06 |
2019-12-11 |
ModernaTX, Inc. |
A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof
|
WO2012019630A1
(en)
|
2010-08-13 |
2012-02-16 |
Curevac Gmbh |
Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded protein
|
US20120058153A1
(en)
|
2010-08-20 |
2012-03-08 |
Selecta Biosciences, Inc. |
Synthetic nanocarrier vaccines comprising proteins obtained or derived from human influenza a virus hemagglutinin
|
PL3981427T3
(pl)
|
2010-08-31 |
2022-09-19 |
Glaxosmithkline Biologicals S.A. |
Pegylowane liposomy do dostarczania rna kodującego immunogen
|
PT4043040T
(pt)
|
2010-08-31 |
2023-03-24 |
Glaxosmithkline Biologicals Sa |
Lipossomas pequenos para entrega de arn que codifica um imunogénio
|
EP3542789A3
(en)
|
2010-08-31 |
2020-01-01 |
GlaxoSmithKline Biologicals SA |
Lipids suitable for liposomal delivery of protein-coding rna
|
US10307372B2
(en)
|
2010-09-10 |
2019-06-04 |
The Johns Hopkins University |
Rapid diffusion of large polymeric nanoparticles in the mammalian brain
|
HUE058896T2
(hu)
|
2010-10-01 |
2022-09-28 |
Modernatx Inc |
N1-metil-pszeudo-uracilt tartalmazó ribonukleinsavak és azok felhasználásai
|
TR201903651T4
(tr)
*
|
2010-10-11 |
2019-04-22 |
Glaxosmithkline Biologicals Sa |
Antijen uygulama platformları.
|
EA201390600A1
(ru)
|
2010-10-22 |
2013-09-30 |
Байнд Терапьютикс, Инк. |
Терапевтические наночастицы с сополимерами с большим молекулярным весом
|
CA3054532C
(en)
|
2010-11-05 |
2022-07-12 |
The Johns Hopkins University |
Compositions and methods relating to reduced mucoadhesion
|
US8853377B2
(en)
|
2010-11-30 |
2014-10-07 |
Shire Human Genetic Therapies, Inc. |
mRNA for use in treatment of human genetic diseases
|
WO2012089225A1
(en)
|
2010-12-29 |
2012-07-05 |
Curevac Gmbh |
Combination of vaccination and inhibition of mhc class i restricted antigen presentation
|
WO2012099805A2
(en)
|
2011-01-19 |
2012-07-26 |
Ocean Nanotech, Llc |
Nanoparticle based immunological stimulation
|
EA033467B1
(ru)
|
2011-01-31 |
2019-10-31 |
Univ Pennsylvania |
Молекула нуклеиновой кислоты для индукции иммунного ответа против герпесвируса и ее применение
|
US20140066363A1
(en)
|
2011-02-07 |
2014-03-06 |
Arun K. Bhunia |
Carbohydrate nanoparticles for prolonged efficacy of antimicrobial peptide
|
WO2012116715A1
(en)
|
2011-03-02 |
2012-09-07 |
Curevac Gmbh |
Vaccination in newborns and infants
|
WO2012113413A1
(en)
|
2011-02-21 |
2012-08-30 |
Curevac Gmbh |
Vaccine composition comprising complexed immunostimulatory nucleic acids and antigens packaged with disulfide-linked polyethyleneglycol/peptide conjugates
|
WO2012116714A1
(en)
|
2011-03-02 |
2012-09-07 |
Curevac Gmbh |
Vaccination in elderly patients
|
JP2014511687A
(ja)
|
2011-03-31 |
2014-05-19 |
モデルナ セラピューティクス インコーポレイテッド |
工学操作された核酸の送達および製剤
|
ES2820369T3
(es)
|
2011-03-31 |
2021-04-20 |
Ingell Tech Holding B V |
Composiciones biodegradables adecuadas para liberación controlada
|
WO2012131106A1
(en)
|
2011-03-31 |
2012-10-04 |
Ingell Technologies Holding B.V. |
Biodegradable compositions suitable for controlled release
|
US8691750B2
(en)
|
2011-05-17 |
2014-04-08 |
Axolabs Gmbh |
Lipids and compositions for intracellular delivery of biologically active compounds
|
AU2012255913A1
(en)
|
2011-05-17 |
2013-11-21 |
Moderna Therapeutics, Inc. |
Engineered nucleic acids and methods of use thereof for non-human vertebrates
|
US20140308363A1
(en)
|
2011-05-31 |
2014-10-16 |
Bind Therapeutics, Inc. |
Drug loaded polymeric nanoparticles and methods of making and using same
|
EP3412282A1
(en)
|
2011-06-02 |
2018-12-12 |
The Regents of the University of California |
Membrane encapsulated nanoparticles and method of use
|
SG10201605500TA
(en)
|
2011-07-06 |
2016-08-30 |
Novartis Ag |
Cationic oil-in-water emulsions
|
JP2014520806A
(ja)
*
|
2011-07-06 |
2014-08-25 |
ノバルティス アーゲー |
Rna分子の送達のための有用なn:p比を有するリポソーム
|
EP3508219A1
(en)
|
2011-07-06 |
2019-07-10 |
GlaxoSmithKline Biologicals S.A. |
Self-replicating rna prime - protein boost vaccines
|
CA2840989A1
(en)
|
2011-07-06 |
2013-01-10 |
Novartis Ag |
Immunogenic combination compositions and uses thereof
|
JP6018197B2
(ja)
|
2011-07-21 |
2016-11-02 |
クローダ インターナショナル パブリック リミティド カンパニー |
分枝状ポリエーテル−ポリアミドブロックコポリマー並びにそれらの製造方法及び使用方法
|
KR20140051357A
(ko)
|
2011-08-26 |
2014-04-30 |
애로우헤드 리서치 코오포레이션 |
In Vivo 핵산 전달용 폴리(비닐 에스테르) 고분자
|
KR20140067070A
(ko)
|
2011-08-31 |
2014-06-03 |
말린크로트 엘엘씨 |
H-포스포네이트에 의한 나노입자 peg 개질
|
KR20140057374A
(ko)
|
2011-09-02 |
2014-05-12 |
노파르티스 아게 |
Hsf1-관련 질환을 치료하기 위한 유기 조성물
|
EP3384938A1
(en)
|
2011-09-12 |
2018-10-10 |
Moderna Therapeutics, Inc. |
Engineered nucleic acids and methods of use thereof
|
US9464124B2
(en)
|
2011-09-12 |
2016-10-11 |
Moderna Therapeutics, Inc. |
Engineered nucleic acids and methods of use thereof
|
US20150017245A1
(en)
|
2011-09-22 |
2015-01-15 |
Bind Therapeutics, Inc. |
Methods of treating cancers with therapeutic nanoparticles
|
WO2013072929A2
(en)
|
2011-09-23 |
2013-05-23 |
Indian Institute Of Technology |
Nanop article based cosmetic composition
|
BR112014008694A2
(pt)
*
|
2011-10-11 |
2017-06-20 |
Novartis Ag |
moléculas de ácido nucleico policistrônico recombinante
|
CA2852064A1
(en)
|
2011-10-14 |
2013-04-18 |
Stc.Unm |
Porous nanoparticle-supported lipid bilayers (protocells) for targeted delivery including transdermal delivery of cargo and methods thereof
|
EP3960726A1
(en)
|
2011-10-18 |
2022-03-02 |
Dicerna Pharmaceuticals, Inc. |
Amine cationic lipids and uses thereof
|
PE20150041A1
(es)
|
2011-10-27 |
2015-01-28 |
Massachusetts Inst Technology |
Derivados de aminoacidos funcionalizados en la terminal n capaces de formar microesferas encapsuladoras de farmaco
|
WO2013078199A2
(en)
|
2011-11-23 |
2013-05-30 |
Children's Medical Center Corporation |
Methods for enhanced in vivo delivery of synthetic, modified rnas
|
WO2013086373A1
(en)
|
2011-12-07 |
2013-06-13 |
Alnylam Pharmaceuticals, Inc. |
Lipids for the delivery of active agents
|
EP2791364A4
(en)
|
2011-12-14 |
2015-11-11 |
Moderna Therapeutics Inc |
METHODS OF RESPONSE TO A BIOLOGICAL THREAT
|
EP2791160B1
(en)
|
2011-12-16 |
2022-03-02 |
ModernaTX, Inc. |
Modified mrna compositions
|
US20130165504A1
(en)
|
2011-12-21 |
2013-06-27 |
modeRNA Therapeutics |
Methods of increasing the viability or longevity of an organ or organ explant
|
CN104936620B
(zh)
|
2012-01-19 |
2019-08-09 |
约翰霍普金斯大学 |
增强粘膜渗透的纳米粒子调配物
|
WO2013113325A1
(en)
|
2012-01-31 |
2013-08-08 |
Curevac Gmbh |
Negatively charged nucleic acid comprising complexes for immunostimulation
|
US9416090B2
(en)
|
2012-02-03 |
2016-08-16 |
Rutgers, The State University Of New Jersey |
Polymeric biomaterials derived from phenolic monomers and their medical uses
|
WO2013120052A1
(en)
|
2012-02-10 |
2013-08-15 |
E. I. Du Pont De Nemours And Company |
Preparation, purification and use of high-x diblock copolymers
|
US10501513B2
(en)
|
2012-04-02 |
2019-12-10 |
Modernatx, Inc. |
Modified polynucleotides for the production of oncology-related proteins and peptides
|
AU2013243951A1
(en)
|
2012-04-02 |
2014-10-30 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of secreted proteins
|
US9254311B2
(en)
|
2012-04-02 |
2016-02-09 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of proteins
|
US9283287B2
(en)
|
2012-04-02 |
2016-03-15 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of nuclear proteins
|
EP3498267A1
(en)
|
2012-05-25 |
2019-06-19 |
CureVac AG |
Reversible immobilization and/or controlled release of nucleic acid containing nanoparticles by (biodegradable) polymer coatings
|
EA201492055A1
(ru)
|
2012-06-08 |
2015-11-30 |
Шир Хьюман Дженетик Терапис, Инк. |
ИНГАЛЯЦИОННАЯ ДОСТАВКА мРНК В НЕЛЕГОЧНЫЕ КЛЕТКИ-МИШЕНИ
|
US9512456B2
(en)
|
2012-08-14 |
2016-12-06 |
Modernatx, Inc. |
Enzymes and polymerases for the synthesis of RNA
|
WO2014093924A1
(en)
*
|
2012-12-13 |
2014-06-19 |
Moderna Therapeutics, Inc. |
Modified nucleic acid molecules and uses thereof
|
WO2014071963A1
(en)
|
2012-11-09 |
2014-05-15 |
Biontech Ag |
Method for cellular rna expression
|
ES2676470T3
(es)
|
2012-11-09 |
2018-07-19 |
Biontech Rna Pharmaceuticals Gmbh |
Método para la expresión de ARN en células
|
EP2922554B1
(en)
|
2012-11-26 |
2022-02-23 |
ModernaTX, Inc. |
Terminally modified rna
|
AU2013355258A1
(en)
|
2012-12-07 |
2015-06-11 |
Alnylam Pharmaceuticals, Inc. |
Improved nucleic acid lipid particle formulations
|
ES2968649T3
(es)
|
2012-12-07 |
2024-05-13 |
Translate Bio Inc |
Nanopartículas lipídicas para la administración de ARNm en los pulmones
|
US20150315541A1
(en)
|
2012-12-13 |
2015-11-05 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for altering cell phenotype
|
US9974845B2
(en)
|
2013-02-22 |
2018-05-22 |
Curevac Ag |
Combination of vaccination and inhibition of the PD-1 pathway
|
ES2887254T3
(es)
*
|
2013-03-08 |
2021-12-22 |
Novartis Ag |
Lípidos y composiciones lipídicas para el suministro de agentes activos
|
US10258698B2
(en)
|
2013-03-14 |
2019-04-16 |
Modernatx, Inc. |
Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions
|
US20160032316A1
(en)
|
2013-03-14 |
2016-02-04 |
The Trustees Of The University Of Pennsylvania |
Purification and Purity Assessment of RNA Molecules Synthesized with Modified Nucleosides
|
CA2903880A1
(en)
|
2013-03-14 |
2014-09-25 |
Shire Human Genetic Therapies, Inc. |
Methods and compositions for delivering mrna coded antibodies
|
ES2967701T3
(es)
|
2013-03-15 |
2024-05-03 |
Translate Bio Inc |
Mejora sinergística de la entrega de ácidos nucleicos mediante formulaciones mezcladas
|
WO2014144039A1
(en)
|
2013-03-15 |
2014-09-18 |
Moderna Therapeutics, Inc. |
Characterization of mrna molecules
|
EP2983804A4
(en)
|
2013-03-15 |
2017-03-01 |
Moderna Therapeutics, Inc. |
Ion exchange purification of mrna
|
EP2971161B1
(en)
|
2013-03-15 |
2018-12-26 |
ModernaTX, Inc. |
Ribonucleic acid purification
|
WO2014152030A1
(en)
|
2013-03-15 |
2014-09-25 |
Moderna Therapeutics, Inc. |
Removal of dna fragments in mrna production process
|
EP3578663A1
(en)
|
2013-03-15 |
2019-12-11 |
ModernaTX, Inc. |
Manufacturing methods for production of rna transcripts
|
US20160017313A1
(en)
|
2013-03-15 |
2016-01-21 |
Moderna Therapeutics, Inc. |
Analysis of mrna heterogeneity and stability
|
TW201534578A
(zh)
|
2013-07-08 |
2015-09-16 |
Daiichi Sankyo Co Ltd |
新穎脂質
|
ES2773309T3
(es)
|
2013-07-25 |
2020-07-10 |
Calder Biosciences Inc |
Proteínas F de pre-fusión de VRS estabilizadas conformacionalmente
|
SG11201510746WA
(en)
|
2013-08-21 |
2016-03-30 |
Curevac Ag |
Respiratory syncytial virus (rsv) vaccine
|
SG11201510747RA
(en)
|
2013-08-21 |
2016-03-30 |
Curevac Ag |
Method for increasing expression of rna-encoded proteins
|
US10385088B2
(en)
|
2013-10-02 |
2019-08-20 |
Modernatx, Inc. |
Polynucleotide molecules and uses thereof
|
CA2927393A1
(en)
|
2013-10-18 |
2015-04-23 |
Moderna Therapeutics, Inc. |
Compositions and methods for tolerizing cellular systems
|
EP3556353A3
(en)
*
|
2014-02-25 |
2020-03-18 |
Merck Sharp & Dohme Corp. |
Lipid nanoparticle vaccine adjuvants and antigen delivery systems
|
PT3134131T
(pt)
|
2014-04-23 |
2022-03-24 |
Modernatx Inc |
Vacinas de ácidos nucleicos
|
CA2951430A1
(en)
|
2014-06-13 |
2015-12-17 |
Glaxosmithkline Biologicals Sa |
Immunogenic combinations
|
US10286086B2
(en)
|
2014-06-19 |
2019-05-14 |
Modernatx, Inc. |
Alternative nucleic acid molecules and uses thereof
|
JP2017523777A
(ja)
|
2014-07-17 |
2017-08-24 |
モデルナティエックス インコーポレイテッドModernaTX,Inc. |
ポリヌクレオチドの末端修飾
|
BR112017012647A2
(pt)
*
|
2014-12-18 |
2018-01-09 |
Glaxosmithkline Biologicals Sa |
composição imunogênica, método para proteção contra ou prevenção de herpes zoster (hz) e/ou neuralgia pós-herpética, e, método para proteção contra, prevenção ou redução da incidência de herpes zoster e/ou neuralgia pós-herpética.
|
WO2016118724A1
(en)
|
2015-01-21 |
2016-07-28 |
Moderna Therapeutics, Inc. |
Lipid nanoparticle compositions
|
WO2016164762A1
(en)
|
2015-04-08 |
2016-10-13 |
Moderna Therapeutics, Inc. |
Polynucleotides encoding low density lipoprotein receptor egf-a and intracellular domain mutants and methods of using the same
|
EP3289083A4
(en)
|
2015-04-27 |
2018-12-19 |
The Trustees Of The University Of Pennsylvania |
Nucleoside-modified rna for inducing an adaptive immune response
|
WO2016201377A1
(en)
|
2015-06-10 |
2016-12-15 |
Moderna Therapeutics, Inc. |
Targeted adaptive vaccines
|
US20180296663A1
(en)
|
2015-06-17 |
2018-10-18 |
Curevac Ag |
Vaccine composition
|
WO2017015463A2
(en)
|
2015-07-21 |
2017-01-26 |
Modernatx, Inc. |
Infectious disease vaccines
|
WO2017015457A1
(en)
|
2015-07-21 |
2017-01-26 |
Modernatx, Inc. |
Ebola vaccine
|
US20190008887A1
(en)
|
2015-07-30 |
2019-01-10 |
ModernaTX Inc. |
Multimeric mrna
|
EP3328394A4
(en)
|
2015-07-30 |
2019-03-13 |
ModernaTX, Inc. |
PEPTIDE CONCATEMERIC EPITAOPE RNA
|
US11564893B2
(en)
|
2015-08-17 |
2023-01-31 |
Modernatx, Inc. |
Methods for preparing particles and related compositions
|
US20180237849A1
(en)
|
2015-08-17 |
2018-08-23 |
Modernatx, Inc. |
Rna mapping/fingerprinting
|
LT3350157T
(lt)
|
2015-09-17 |
2022-02-25 |
Modernatx, Inc. |
Junginiai ir kompozicijos terapinei medžiagai teikti intraceliuliniu būdu
|
JP6990176B2
(ja)
|
2015-10-05 |
2022-02-03 |
モデルナティエックス インコーポレイテッド |
メッセンジャーリボ核酸薬物の治療投与のための方法
|
WO2017066789A1
(en)
|
2015-10-16 |
2017-04-20 |
Modernatx, Inc. |
Mrna cap analogs with modified sugar
|
WO2017070601A1
(en)
|
2015-10-22 |
2017-04-27 |
Modernatx, Inc. |
Nucleic acid vaccines for varicella zoster virus (vzv)
|
CN109310751A
(zh)
|
2015-10-22 |
2019-02-05 |
摩登纳特斯有限公司 |
广谱流感病毒疫苗
|
AU2016341311B2
(en)
|
2015-10-22 |
2023-11-16 |
Modernatx, Inc. |
Respiratory syncytial virus vaccine
|
AU2016342376A1
(en)
|
2015-10-22 |
2018-06-07 |
Modernatx, Inc. |
Sexually transmitted disease vaccines
|
EP3364950A4
(en)
|
2015-10-22 |
2019-10-23 |
ModernaTX, Inc. |
VACCINES AGAINST TROPICAL DISEASES
|
CA3003090A1
(en)
|
2015-10-22 |
2017-04-27 |
Modernatx, Inc. |
Cancer vaccines
|
WO2017070613A1
(en)
|
2015-10-22 |
2017-04-27 |
Modernatx, Inc. |
Human cytomegalovirus vaccine
|
HUE059127T2
(hu)
|
2015-10-22 |
2022-10-28 |
Modernatx Inc |
Légúti vírusok elleni vakcinák
|
BR112018008090A2
(pt)
|
2015-10-22 |
2018-11-13 |
Modernatx Inc |
vacina de vírus do herpes simplex.
|
AU2016366978B2
(en)
|
2015-12-10 |
2022-07-28 |
Modernatx, Inc. |
Compositions and methods for delivery of therapeutic agents
|
MA43568A
(fr)
|
2015-12-17 |
2018-11-14 |
Modernatx Inc |
Polynucléotides codant pour la méthylmalonyl-coa mutase
|
US10465190B1
(en)
|
2015-12-23 |
2019-11-05 |
Modernatx, Inc. |
In vitro transcription methods and constructs
|
US20210206818A1
(en)
|
2016-01-22 |
2021-07-08 |
Modernatx, Inc. |
Messenger ribonucleic acids for the production of intracellular binding polypeptides and methods of use thereof
|
JP7114485B2
(ja)
|
2016-05-18 |
2022-08-08 |
モデルナティエックス インコーポレイテッド |
ファブリー病の治療のためのα-ガラクトシダーゼAをコードするポリヌクレオチド
|
US20190382774A1
(en)
|
2016-05-18 |
2019-12-19 |
Modernatx, Inc. |
Polyribonucleotides containing reduced uracil content and uses thereof
|
AU2017268399B2
(en)
|
2016-05-18 |
2023-01-12 |
Modernatx, Inc. |
mRNA combination therapy for the treatment of cancer
|
US20190298657A1
(en)
|
2016-05-18 |
2019-10-03 |
Modernatx, Inc. |
Polynucleotides Encoding Acyl-CoA Dehydrogenase, Very Long-Chain for the Treatment of Very Long-Chain Acyl-CoA Dehydrogenase Deficiency
|
CN115837014A
(zh)
|
2016-05-18 |
2023-03-24 |
摩登纳特斯有限公司 |
编码松弛素的多核苷酸
|
EP3458108A4
(en)
|
2016-05-18 |
2020-04-22 |
ModernaTX, Inc. |
POLYNUCLEOTIDES FOR CODING THE TRANSMEMBRANE CONDUCTIVE REGULATOR OF CYSTIC FIBROSE FOR TREATING CYSTIC FIBROSE
|
WO2017201342A1
(en)
|
2016-05-18 |
2017-11-23 |
Modernatx, Inc. |
Polynucleotides encoding jagged1 for the treatment of alagille syndrome
|
EP3458106A4
(en)
|
2016-05-18 |
2020-03-18 |
Modernatx, Inc. |
POLYNUCLEOTIDES ENCODING LIPOPROTEIN LIPASE FOR THE TREATMENT OF HYPERLIPIDEMIA
|
MA45032A
(fr)
|
2016-05-18 |
2019-03-27 |
Fundacion Para La Investig Medica Aplicada |
Polynucléotides codant pour la porphobilinogène désaminase destinés au traitement de la porphyrie intermittente aiguë
|
US11001861B2
(en)
|
2016-05-18 |
2021-05-11 |
Modernatx, Inc. |
Polynucleotides encoding galactose-1-phosphate uridylyltransferase for the treatment of galactosemia type 1
|
SG11201810162PA
(en)
|
2016-05-18 |
2018-12-28 |
Modernatx Inc |
Polynucleotides encoding citrin for the treatment of citrullinemia type 2
|
JP2019525901A
(ja)
|
2016-06-14 |
2019-09-12 |
モデルナティエックス インコーポレイテッドModernaTX,Inc. |
脂質ナノ粒子の安定化製剤
|
CN109937253B
(zh)
|
2016-09-14 |
2023-06-30 |
摩登纳特斯有限公司 |
高纯度rna组合物及其制备方法
|
WO2018075980A1
(en)
|
2016-10-21 |
2018-04-26 |
Modernatx, Inc. |
Human cytomegalovirus vaccine
|
WO2018081462A1
(en)
|
2016-10-26 |
2018-05-03 |
Modernatx, Inc. |
Methods and compositions for rna mapping
|
CA3042015A1
(en)
|
2016-10-26 |
2018-05-03 |
Modernatx, Inc. |
Messenger ribonucleic acids for enhancing immune responses and methods of use thereof
|
EP3532094A1
(en)
|
2016-10-26 |
2019-09-04 |
CureVac AG |
Lipid nanoparticle mrna vaccines
|
MA46766A
(fr)
|
2016-11-11 |
2019-09-18 |
Modernatx Inc |
Vaccin antigrippal
|
MA50335A
(fr)
|
2016-12-08 |
2020-08-19 |
Modernatx Inc |
Vaccins à acide nucléique contre des virus respiratoires
|
EP3555289A1
(en)
|
2016-12-13 |
2019-10-23 |
ModernaTX, Inc. |
Rna affinity purification
|
US20180243225A1
(en)
|
2017-01-25 |
2018-08-30 |
Modernatx, Inc. |
Ebola/marburg vaccines
|
EP3577221A4
(en)
|
2017-02-01 |
2020-12-23 |
ModernaTX, Inc. |
SECONDARY POLYNUCLEOTIDE STRUCTURE
|
CN110430894A
(zh)
|
2017-02-01 |
2019-11-08 |
莫得纳特斯公司 |
编码活化致癌基因突变肽的免疫调节治疗性mrna组合物
|
JP2020506189A
(ja)
|
2017-02-01 |
2020-02-27 |
モデルナティーエックス, インコーポレイテッド |
Rna癌ワクチン
|
EP3582790A4
(en)
|
2017-02-16 |
2020-11-25 |
ModernaTX, Inc. |
VERY POWERFUL IMMUNOGENIC COMPOSITIONS
|
US20200368162A1
(en)
|
2017-02-24 |
2020-11-26 |
Modernatx, Inc. |
Nucleic Acid-Based Therapy of Muscular Dystrophies
|
EP3595713A4
(en)
|
2017-03-15 |
2021-01-13 |
ModernaTX, Inc. |
RESPIRATORY SYNCYTIAL VIRUS VACCINE
|
WO2018170245A1
(en)
|
2017-03-15 |
2018-09-20 |
Modernatx, Inc. |
Broad spectrum influenza virus vaccine
|
RS63953B1
(sr)
|
2017-03-15 |
2023-02-28 |
Modernatx Inc |
Jedinjenje i kompozicije za intracelularnu isporuku terapeutskih sredstava
|
US11045540B2
(en)
|
2017-03-15 |
2021-06-29 |
Modernatx, Inc. |
Varicella zoster virus (VZV) vaccine
|
WO2018170256A1
(en)
|
2017-03-15 |
2018-09-20 |
Modernatx, Inc. |
Herpes simplex virus vaccine
|
US20200030432A1
(en)
|
2017-03-17 |
2020-01-30 |
Modernatx, Inc. |
Zoonotic disease rna vaccines
|
WO2018175783A1
(en)
|
2017-03-22 |
2018-09-27 |
Modernatx, Inc. |
Rna bacterial vaccines
|
MA48047A
(fr)
|
2017-04-05 |
2020-02-12 |
Modernatx Inc |
Réduction ou élimination de réponses immunitaires à des protéines thérapeutiques administrées par voie non intraveineuse, par exemple par voie sous-cutanée
|
MA49463A
(fr)
|
2017-04-26 |
2021-05-05 |
Modernatx Inc |
Vaccin contre le virus de l'herpès simplex
|
US11786607B2
(en)
|
2017-06-15 |
2023-10-17 |
Modernatx, Inc. |
RNA formulations
|
WO2018232355A1
(en)
|
2017-06-15 |
2018-12-20 |
Modernatx, Inc. |
Rna antibodies
|
US11866696B2
(en)
|
2017-08-18 |
2024-01-09 |
Modernatx, Inc. |
Analytical HPLC methods
|
US20200254086A1
(en)
|
2017-08-18 |
2020-08-13 |
Moderna TX, Inc. |
Efficacious mrna vaccines
|
CN111212905A
(zh)
|
2017-08-18 |
2020-05-29 |
摩登纳特斯有限公司 |
Rna聚合酶变体
|
EP3668979A4
(en)
|
2017-08-18 |
2021-06-02 |
Modernatx, Inc. |
METHOD OF HPLC ANALYSIS
|
US10653767B2
(en)
|
2017-09-14 |
2020-05-19 |
Modernatx, Inc. |
Zika virus MRNA vaccines
|
US20190192646A1
(en)
|
2017-11-03 |
2019-06-27 |
Modernatx, Inc. |
Salmonella vaccines
|
CA3083102A1
(en)
|
2017-11-21 |
2019-05-31 |
Modernatx, Inc. |
Epstein-barr virus vaccines
|
US11911453B2
(en)
|
2018-01-29 |
2024-02-27 |
Modernatx, Inc. |
RSV RNA vaccines
|
EP3813848A4
(en)
|
2018-06-27 |
2022-07-20 |
ModernaTX, Inc. |
EPITOPE SELECTION FOR PERSONALIZED CANCER VACCINE
|
US20220054653A1
(en)
|
2018-09-13 |
2022-02-24 |
Modernatx, Inc. |
Modified mrna for the treatment of progressive familial intrahepatic cholestasis disorders
|
EP3852732A1
(en)
|
2018-09-19 |
2021-07-28 |
ModernaTX, Inc. |
Peg lipids and uses thereof
|
WO2020061295A1
(en)
|
2018-09-19 |
2020-03-26 |
Modernatx, Inc. |
High-purity peg lipids and uses thereof
|
JP7410135B2
(ja)
|
2018-09-19 |
2024-01-09 |
モデルナティエックス インコーポレイテッド |
治療薬の細胞内送達のための化合物及び組成物
|
US20220125899A1
(en)
|
2018-11-07 |
2022-04-28 |
Modernatx, Inc. |
Rna cancer vaccines
|
JP2022521094A
(ja)
|
2019-02-20 |
2022-04-05 |
モデルナティエックス インコーポレイテッド |
共転写キャッピング用rnaポリメラーゼバリアント
|
MX2021011031A
(es)
|
2019-03-11 |
2021-12-10 |
Modernatx Inc |
Proceso de transcripción in vitro en lotes alimentados.
|
EP3938379A4
(en)
|
2019-03-15 |
2023-02-22 |
ModernaTX, Inc. |
HIV RNA VACCINE
|
JP2022535006A
(ja)
|
2019-05-31 |
2022-08-04 |
モデルナティエックス インコーポレイテッド |
増殖t細胞アッセイ
|
CN114269918A
(zh)
|
2019-08-14 |
2022-04-01 |
摩登纳特斯有限公司 |
用于纯化体外转录的下游产物的方法
|
CA3154082A1
(en)
|
2019-09-11 |
2021-03-18 |
Modernatx, Inc. |
Human cytomegalovirus vaccine
|
CA3155014A1
(en)
|
2019-09-19 |
2021-03-25 |
Modernatx, Inc. |
Cap guides and methods of use thereof for rna mapping
|